MBTPS1 and metabolic dysfunction-associated steatohepatitis: Here we have explored the therapeutic efficacy of Etrasimod, a selective S1P receptor 1, 4, and 5 modulator in comparison with Amiselimod, a selective S1P receptor 1 modulator, in attenuating murine NASH and associated intrahepatic leukocyte populations via antagonism of the S1P signaling axis.